Aim: Rare gene variations are thought to confer substantial risk for schizophrenia. We performed a threestage study to identify rare variations that have a strong impact on the risk of developing schizophrenia.
A LARGE NUMBER of genetic variations, ranging from those that are common to rare, contribute to the genetic risk for schizophrenia (MIM 181500). 1 Over 100 common loci with small effects have been associated with schizophrenia via genome-wide association studies (GWAS). [2] [3] [4] Several rare copy number variations with large effects have also been found to contribute to schizophrenia liability. [5] [6] [7] Rare sequence variations have been shown to strongly impact the risk of developing schizophrenia via whole-exome sequencing (WES) studies. [8] [9] [10] Of note, Singh et al. 11 reported a significant genome-wide association of rare loss-of-function variations in the SETD1A gene with schizophrenia. In addition, de novo loss-of-function and functional synonymous variations in SETD1A showed genomewide enrichment in schizophrenia. 12 WES and whole-genome sequencing studies of multiplex schizophrenia families may be useful in identifying rare risk variations with large effcts. [13] [14] [15] [16] [17] Recently, we performed WES with three families that each included a proband, an affected sibling, and parents. 18 We identified a total of 15 rare truncating (nonsense and frameshift) variations, but no rare de novo non-synonymous variations. In a follow-up case-control study, we found no significant associations between the rare truncating variations and schizophrenia. When conducting WES with the three families, we prioritized rare truncating variations. Therefore, it is likely that we did not capture other kinds of rare variations.
Here, we performed a three-stage study to identify the genes with rare variations that play a substantial role in conferring risk for schizophrenia. In the first stage, we prioritized rare missense variations present in both affected siblings in each family using WES data. Recurrent rare missense variations were only identified in the PDCD11 gene. In the second stage, we performed targeted resequencing of the PDCD11 coding region in 96 patients. In the third stage, we conducted an association study between schizophrenia and rare PDCD11 variation, identified via WES and targeted resequencing, in a total of 1357 patients and 1394 controls.
METHODS Participants
This study was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of each participating institute. All participants were of Japanese descent, and all gave written informed consent.
In our previous WES study, we included 12 individuals from three families, with a proband with schizophrenia, a sibling affected by schizophrenia, and parents from each family (Table 1) . 18 Diagnoses of each family member were made using DSM-IV criteria, as previously described. 19 For targeted resequencing of the PDCD11 coding region, we included 96 schizophrenia patients (Table 2) . These individuals were not included in the case-control study. For the case-control study, we used two independent samples ( Table 2 ). The Niigata sample comprised 638 schizophrenia patients and 675 controls. 20 The Kobe sample comprised 719 patients with schizophrenia or schizoaffective disorder and 719 controls. 21 The patients were diagnosed according to DSM-IV or DSM-5 criteria. Controls had no personal or family history (first-degree relatives) of psychiatric disorders.
WES
We performed WES with 12 individuals from three families (Table 1) , as previously reported. 18 In brief, we prepared exome libraries using the SureSelect Human All Exon V4 or V5 Kit (Agilent, Santa Clara, CA, USA) and used the HiSeq2000 system (Illumina, San Diego, CA, USA) for sequencing.
To prioritize variations, we applied the following filtering steps (Table 3) . First, we included variations covered with reads ≥ 10. Second, we included variations identified in both affected siblings in each family. Third, we included variations with a dominant or recessive inheritance pattern. Fourth, we included missense variations. In our previous study, we analyzed truncating variations and found no de novo non-synonymous variation. 18 23 Finally, we selected two rare missense variations in the PDCD11 gene among 89 prioritized variations in 88 genes. To validate two rare missense PDCD11 variations, we performed Sanger sequencing using a 3130xl Genetic Analyzer (Applied Biosystems, Foster City, CA, USA), as previously described. 24 Targeted resequencing of the PDCD11 coding region
The Contract Development & Manufacturing Center of Takara Bio Inc. (Mie, Japan) performed targeted resequencing of the PDCD11 coding region in 96 patients. For targeted resequencing of the PDCD11 coding region, we designed a TruSeq Custom Amplicon (Illumina) using DesignStudio (Illumina). The cumulative target size was 7514 bp and 51 amplicons, covering 99% of the target region with a total gap distance of 10 bp. Sequencing was performed using a MiSeq system (Illumina) with the paired-end module for 150-bp reads. Paired-end sequence reads were mapped against the reference human genome (UCSC hg19) and variations were identified using the MiSeq Reporter v2.4.60 (Illumina).
We selected rare non-synonymous variations with GERP scores > 5 and mutant allele frequency < 0.01. To validate these variations, we performed Sanger sequencing.
Case-control study
We performed an association study between schizophrenia and four rare non-synonymous PDCD11 variations, identified via WES and targeted resequencing, in a total of 1357 patients and 1394 controls. We genotyped three missense variations, p.(Asp961Asn), p.(Val1240Leu), and p.(Arg1837His), using the TaqMan 5 0 -exonuclease assay (Applied Biosystems; Table S1), as previously described. 20 We genotyped one in-frame deletion, p.(Phe1835del), using fragment analysis. We used 5 0 -FAM-CCCAAGGCAT-CATGGGAGTT-3 0 and 5 0 -TTGACAGTGTCCCACA-GAGC-3 0 as forward and reverse primer sequences, respectively. We analyzed the length of polymerase chain reaction products using the 3130xl Genetic Analyzer with GeneMapper v3.7 software (Applied Biosystems). 
Statistical analysis
We assessed the Hardy-Weinberg equilibrium using the χ 2 -test for goodness-of-fit. We tested allelic associations using Fisher's exact test. We performed a genebased analysis using the sequence kernel association test (SKAT; http://www.hsph.harvard.edu/skat/). 25 Files were formatted for the analysis using PLINK (http://pngu.mgh.harvard.edu/purcell/plink/). 26 Using two case-control samples, we performed a singlevariant meta-analysis in a random-effect model and a gene-based meta-analysis, using EZR v1.30 (https:// cran.r-project.org/web/packages/RcmdrPlugin.EZR/ind ex.html) 27 and MetaSKAT (https://cran.r-project.org/ web/packages/MetaSKAT/), 28 respectively. We conducted a power calculation using the Genetic Power Calculator (http://pngu.mgh.harvard.edu/~purcell/gpc/). 29 
RESULTS
In the first stage, we used the WES data from the three families with affected siblings 18 and prioritized a total of 89 rare missense variations in 88 genes: 24 in family #1, 32 in family #2, and 33 in family #3 (Table 3) . Among these 88 genes, only PDCD11 had recurrent variations (Tables 1 and 4 ; Fig. 1 (Table 1) . In family #2, the mutant allele of p.(Asp961Asn) was transmitted from the unaffected mother (I-2) to two siblings (II-1 and II-3) with schizophrenia.
In the second stage, we detected 28 variations in 96 patients via targeted resequencing of the PDCD11 coding region (Table S2 ). Among these, we selected three rare non-synonymous variations with GERP scores > 5 (Table 4 ; Fig. 1 In the third stage, we conducted an association study between four rare non-synonymous PDCD11 variations and schizophrenia in the Niigata and Kobe samples (Table 5 ). All four variations showed no significant deviations from the Hardy-Weinberg equilibrium in the patient or control groups in the Niigata and Kobe samples (data not shown). We found no significant association between p.(Asp961Asn) and schizophrenia in the Niigata or Kobe samples. In the Kobe sample, the mutant allele of p.(Val1240Leu) was nominally significantly lower in patients compared with controls (0 vs 0.0042; P = 0.03). However, this association was not significant after the multiple testing correction. A singlevariant meta-analysis showed no significant association between p.(Asp961Asn) or p.(Val1240Leu) with schizophrenia. Although we identified p.(Phe1835del) exclusively in two patients in the Kobe sample, we found no significant association between this in-frame deletion and schizophrenia in the Niigata, Kobe, or combined samples. We did not detect p.(Arg1837His) in the Niigata or Kobe samples. In the gene-based analysis, rare nonsynonymous PDCD11 variations were not significantly associated with schizophrenia in the Niigata or Kobe samples (SKAT P = 0.84 and 0.24, respectively). In the gene-based meta-analysis, we also found no significant associations between the above variables (MetaSKAT P = 0.67).
DISCUSSION
PDCD11 is a promising candidate gene for schizophrenia. This gene is located within the third-rank GWAS region (chr10:104,423,800-105,165,583) 2 Interestingly, overlap has been documented between genes in the GWAS loci associated with schizophrenia and those with de novo non-synonymous variations in patients with schizophrenia detected via WES, 2 suggesting that GWAS and WES are complementary for identifying risk genes for schizophrenia. Using WES data from three families, 18 we identified p.(Asp961Asn) and p.(Val1240Leu) in PDCD11. These variations were present in both affected siblings within families, but were transmitted from unaffected parents. Incomplete co-segregation was also the case in other studies of multiplex schizophrenia families. 13, 14, 17 In addition to p.(Asp961Asn) and p.(Val1240Leu) identified via WES, we also detected p.(Phe1835del) and p.(Arg1837His) via target resequencing of PDCD11. We predicted these four variations to be damaging via in silico analysis, although functional analyses will be needed to determine the functional implications of these variations. These four putatively functional PDCD11 variations were not associated with schizophrenia in a total of 1357 patients and 1394 controls. However, p.(Phe1835del) and p.(Arg1837His) were exclusively identified in three and one patients, respectively (Table S3 ). These variations were not registered in dbSNP (https://www. ncbi.nlm.nih.gov/projects/SNP/index.html) or HGVD (Table 4 ). In the Exome Aggregation Consortium database (ExAC; http://exac.broadinstitute.org/), p.(Phe1835del) was not identified in 8654 East Asian individuals, and p.(Arg1837His) was not registered. Our negative results may be due to an insufficient sample size (1357 patients and 1394 controls). When the genotypic relative risk was set to 5.0 for heterozygous risk allele carriers under the dominant model of inheritance, our sample size had a statistical power of 0.80 with α = 0.05 to find an association between rare PDCD11 variations and schizophrenia, assuming a risk allele frequency of 0.001 and a disease prevalence of 0.01. PDCD11, located on 10q24.33, is included within the third-rank risk locus for schizophrenia in the GWAS of the Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2 as mentioned above. Another GWAS identified 10q24.32 (rs10883795 and rs10883765) as a risk locus for schizophrenia in the Han Chinese population. 4 Interestingly, rs10883795 and rs10883765 were associated with the mRNA expression levels of nearby genes, including PDCD11. 4 In the present study, we tested rare but not common PDCD11 variations for associations with schizophrenia. Therefore, our 30 Screening a cDNA library from a human astrocytic cell line, Sweet et al. 31 revealed that PDCD11 binds NF-κB by the yeast two-hybrid system. A dominant negative mutant of Pdcd11 inhibited T cell-receptor-induced Fas ligand upregulation and apoptosis, whereas overexpression of full-length Pdcd11 promoted Fas ligand transcription and apoptosis through NF-κB activation. 32 Abnormal NF-κB expression has been observed in the brains of patients with schizophrenia, 33, 34 although results have been inconsistent. Roussos et al. 33 reported lower expression of the NF-κB gene complex in all four examined brain regions (dorsolateral prefrontal cortex, middle temporal area gyrus, temporopolar area, and anterior cingulate cortex) using microarray data. NF-κB gene and protein levels, as well as nuclear activation, were found to be lower in the superior temporal gyrus of people with schizophrenia, as revealed using independent samples. In contrast, Volk et al. 34 found higher mRNA levels of NF-κB in the prefrontal cortex. Given these findings, one may speculate that PDCD11 variations cause dysfunction in NF-κB signaling in the pathogenesis of schizophrenia. However, the functions of PDCD11 in the brain remain unknown.
In conclusion, our data provide no evidence for the contribution of rare PDCD11 variations to the risk of schizophrenia in the Japanese population.
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